nodes	percent_of_prediction	percent_of_DWPC	metapath
Albendazole—ABCB1—ovarian cancer	0.223	1	CbGaD
Albendazole—TUBB4B—Vinorelbine—ovarian cancer	0.22	0.375	CbGbCtD
Albendazole—TUBB4B—Paclitaxel—ovarian cancer	0.155	0.263	CbGbCtD
Albendazole—TUBB4B—Docetaxel—ovarian cancer	0.112	0.19	CbGbCtD
Albendazole—ABCB1—Topotecan—ovarian cancer	0.0223	0.0379	CbGbCtD
Albendazole—ABCB1—Vinorelbine—ovarian cancer	0.0157	0.0267	CbGbCtD
Albendazole—CYP3A4—Topotecan—ovarian cancer	0.0133	0.0227	CbGbCtD
Albendazole—ABCB1—Paclitaxel—ovarian cancer	0.011	0.0188	CbGbCtD
Albendazole—CYP3A4—Vinorelbine—ovarian cancer	0.0094	0.016	CbGbCtD
Albendazole—ABCB1—Docetaxel—ovarian cancer	0.00797	0.0136	CbGbCtD
Albendazole—TUBA1A—oviduct—ovarian cancer	0.0075	0.132	CbGeAlD
Albendazole—CYP3A4—Paclitaxel—ovarian cancer	0.00661	0.0112	CbGbCtD
Albendazole—ABCB1—Doxorubicin—ovarian cancer	0.00594	0.0101	CbGbCtD
Albendazole—TUBB4B—oviduct—ovarian cancer	0.005	0.088	CbGeAlD
Albendazole—CYP3A4—Docetaxel—ovarian cancer	0.00478	0.00812	CbGbCtD
Albendazole—CYP3A4—Doxorubicin—ovarian cancer	0.00356	0.00605	CbGbCtD
Albendazole—TUBA1A—myometrium—ovarian cancer	0.0024	0.0423	CbGeAlD
Albendazole—TUBA1A—embryo—ovarian cancer	0.00231	0.0406	CbGeAlD
Albendazole—Pancytopenia—Altretamine—ovarian cancer	0.00228	0.0317	CcSEcCtD
Albendazole—TUBA1A—epithelium—ovarian cancer	0.00188	0.0332	CbGeAlD
Albendazole—TUBA1A—uterine cervix—ovarian cancer	0.00187	0.0329	CbGeAlD
Albendazole—TUBA1A—decidua—ovarian cancer	0.00178	0.0313	CbGeAlD
Albendazole—Alopecia reversible—Epirubicin—ovarian cancer	0.00176	0.0244	CcSEcCtD
Albendazole—TUBA1A—endometrium—ovarian cancer	0.00169	0.0297	CbGeAlD
Albendazole—Alopecia reversible—Doxorubicin—ovarian cancer	0.00162	0.0226	CcSEcCtD
Albendazole—TUBB4B—myometrium—ovarian cancer	0.0016	0.0282	CbGeAlD
Albendazole—TUBA1A—gonad—ovarian cancer	0.00157	0.0276	CbGeAlD
Albendazole—TUBA1A—uterus—ovarian cancer	0.00156	0.0274	CbGeAlD
Albendazole—TUBB4B—embryo—ovarian cancer	0.00154	0.0271	CbGeAlD
Albendazole—Vertigo—Altretamine—ovarian cancer	0.0015	0.0209	CcSEcCtD
Albendazole—Leukopenia—Altretamine—ovarian cancer	0.0015	0.0208	CcSEcCtD
Albendazole—TUBA1A—female reproductive system—ovarian cancer	0.0014	0.0246	CbGeAlD
Albendazole—Thrombocytopenia—Altretamine—ovarian cancer	0.00134	0.0186	CcSEcCtD
Albendazole—TUBA1A—bone marrow—ovarian cancer	0.00132	0.0233	CbGeAlD
Albendazole—TUBA1A—female gonad—ovarian cancer	0.00127	0.0224	CbGeAlD
Albendazole—TUBA1A—vagina—ovarian cancer	0.00126	0.0223	CbGeAlD
Albendazole—TUBB4B—uterine cervix—ovarian cancer	0.00124	0.0219	CbGeAlD
Albendazole—TUBB4B—decidua—ovarian cancer	0.00119	0.0209	CbGeAlD
Albendazole—TUBA1A—testis—ovarian cancer	0.00113	0.0199	CbGeAlD
Albendazole—TUBB4B—endometrium—ovarian cancer	0.00113	0.0198	CbGeAlD
Albendazole—Renal failure acute—Chlorambucil—ovarian cancer	0.00107	0.0149	CcSEcCtD
Albendazole—TUBB4B—gonad—ovarian cancer	0.00104	0.0184	CbGeAlD
Albendazole—TUBB4B—uterus—ovarian cancer	0.00104	0.0183	CbGeAlD
Albendazole—Aplastic anaemia—Vinorelbine—ovarian cancer	0.000973	0.0135	CcSEcCtD
Albendazole—Renal failure acute—Melphalan—ovarian cancer	0.000933	0.013	CcSEcCtD
Albendazole—TUBB4B—female reproductive system—ovarian cancer	0.000932	0.0164	CbGeAlD
Albendazole—Dizziness—Altretamine—ovarian cancer	0.000904	0.0125	CcSEcCtD
Albendazole—TUBB4B—bone marrow—ovarian cancer	0.00088	0.0155	CbGeAlD
Albendazole—Vomiting—Altretamine—ovarian cancer	0.000869	0.0121	CcSEcCtD
Albendazole—TUBB4B—female gonad—ovarian cancer	0.000848	0.0149	CbGeAlD
Albendazole—TUBB4B—vagina—ovarian cancer	0.000843	0.0149	CbGeAlD
Albendazole—TUBA1A—lymph node—ovarian cancer	0.000818	0.0144	CbGeAlD
Albendazole—Nausea—Altretamine—ovarian cancer	0.000812	0.0113	CcSEcCtD
Albendazole—Pancytopenia—Chlorambucil—ovarian cancer	0.000811	0.0113	CcSEcCtD
Albendazole—Neutropenia—Chlorambucil—ovarian cancer	0.000799	0.0111	CcSEcCtD
Albendazole—Liver function test abnormal—Melphalan—ovarian cancer	0.000795	0.011	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Chlorambucil—ovarian cancer	0.000755	0.0105	CcSEcCtD
Albendazole—TUBB4B—testis—ovarian cancer	0.000752	0.0133	CbGeAlD
Albendazole—Body temperature increased—Carboplatin—ovarian cancer	0.000746	0.0104	CcSEcCtD
Albendazole—Pancytopenia—Topotecan—ovarian cancer	0.000722	0.01	CcSEcCtD
Albendazole—Neutropenia—Topotecan—ovarian cancer	0.000711	0.00987	CcSEcCtD
Albendazole—Pancytopenia—Melphalan—ovarian cancer	0.000707	0.00981	CcSEcCtD
Albendazole—CYP1A1—epithelium—ovarian cancer	0.000703	0.0124	CbGeAlD
Albendazole—CYP1A1—uterine cervix—ovarian cancer	0.000697	0.0123	CbGeAlD
Albendazole—Neutropenia—Melphalan—ovarian cancer	0.000696	0.00966	CcSEcCtD
Albendazole—Erythema multiforme—Chlorambucil—ovarian cancer	0.000646	0.00897	CcSEcCtD
Albendazole—Hepatobiliary disease—Topotecan—ovarian cancer	0.000641	0.0089	CcSEcCtD
Albendazole—Hepatobiliary disease—Melphalan—ovarian cancer	0.000628	0.00871	CcSEcCtD
Albendazole—Pancytopenia—Vinorelbine—ovarian cancer	0.000618	0.00857	CcSEcCtD
Albendazole—Neutropenia—Vinorelbine—ovarian cancer	0.000608	0.00844	CcSEcCtD
Albendazole—Alopecia—Chlorambucil—ovarian cancer	0.000604	0.00839	CcSEcCtD
Albendazole—Hepatitis—Melphalan—ovarian cancer	0.000596	0.00827	CcSEcCtD
Albendazole—Urinary tract disorder—Melphalan—ovarian cancer	0.000588	0.00817	CcSEcCtD
Albendazole—Urethral disorder—Melphalan—ovarian cancer	0.000584	0.00811	CcSEcCtD
Albendazole—CYP1A1—uterus—ovarian cancer	0.000581	0.0102	CbGeAlD
Albendazole—Immune system disorder—Topotecan—ovarian cancer	0.00055	0.00763	CcSEcCtD
Albendazole—Hepatobiliary disease—Vinorelbine—ovarian cancer	0.000548	0.00761	CcSEcCtD
Albendazole—Renal failure acute—Paclitaxel—ovarian cancer	0.000548	0.00761	CcSEcCtD
Albendazole—TUBB4B—lymph node—ovarian cancer	0.000545	0.00961	CbGeAlD
Albendazole—Agranulocytosis—Vinorelbine—ovarian cancer	0.000541	0.00751	CcSEcCtD
Albendazole—Immune system disorder—Melphalan—ovarian cancer	0.000538	0.00747	CcSEcCtD
Albendazole—Alopecia—Topotecan—ovarian cancer	0.000538	0.00747	CcSEcCtD
Albendazole—Leukopenia—Chlorambucil—ovarian cancer	0.000533	0.00739	CcSEcCtD
Albendazole—Alopecia—Melphalan—ovarian cancer	0.000526	0.00731	CcSEcCtD
Albendazole—CYP1A1—female reproductive system—ovarian cancer	0.000522	0.0092	CbGeAlD
Albendazole—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000475	0.0066	CcSEcCtD
Albendazole—CYP1A1—female gonad—ovarian cancer	0.000475	0.00837	CbGeAlD
Albendazole—Leukopenia—Topotecan—ovarian cancer	0.000474	0.00658	CcSEcCtD
Albendazole—CYP1A1—vagina—ovarian cancer	0.000472	0.00832	CbGeAlD
Albendazole—Immune system disorder—Vinorelbine—ovarian cancer	0.00047	0.00653	CcSEcCtD
Albendazole—Liver function test abnormal—Paclitaxel—ovarian cancer	0.000467	0.00649	CcSEcCtD
Albendazole—ABCB1—myometrium—ovarian cancer	0.000465	0.00819	CbGeAlD
Albendazole—Leukopenia—Melphalan—ovarian cancer	0.000464	0.00645	CcSEcCtD
Albendazole—Alopecia—Vinorelbine—ovarian cancer	0.00046	0.00639	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000448	0.00622	CcSEcCtD
Albendazole—ABCB1—embryo—ovarian cancer	0.000447	0.00788	CbGeAlD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000439	0.00609	CcSEcCtD
Albendazole—Thrombocytopenia—Topotecan—ovarian cancer	0.000423	0.00588	CcSEcCtD
Albendazole—Skin disorder—Topotecan—ovarian cancer	0.00042	0.00583	CcSEcCtD
Albendazole—Pancytopenia—Paclitaxel—ovarian cancer	0.000415	0.00577	CcSEcCtD
Albendazole—Thrombocytopenia—Melphalan—ovarian cancer	0.000414	0.00575	CcSEcCtD
Albendazole—Skin disorder—Melphalan—ovarian cancer	0.000411	0.00571	CcSEcCtD
Albendazole—Neutropenia—Paclitaxel—ovarian cancer	0.000409	0.00568	CcSEcCtD
Albendazole—Vertigo—Vinorelbine—ovarian cancer	0.000407	0.00565	CcSEcCtD
Albendazole—Leukopenia—Vinorelbine—ovarian cancer	0.000406	0.00563	CcSEcCtD
Albendazole—Mebendazole—ABCB1—ovarian cancer	0.000398	1	CrCbGaD
Albendazole—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000397	0.00551	CcSEcCtD
Albendazole—Liver function test abnormal—Docetaxel—ovarian cancer	0.000396	0.0055	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.000387	0.00537	CcSEcCtD
Albendazole—Urticaria—Chlorambucil—ovarian cancer	0.000386	0.00536	CcSEcCtD
Albendazole—Body temperature increased—Chlorambucil—ovarian cancer	0.000384	0.00533	CcSEcCtD
Albendazole—Abdominal pain—Chlorambucil—ovarian cancer	0.000384	0.00533	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000383	0.00532	CcSEcCtD
Albendazole—CYP3A4—female reproductive system—ovarian cancer	0.000383	0.00675	CbGeAlD
Albendazole—Aplastic anaemia—Epirubicin—ovarian cancer	0.000374	0.0052	CcSEcCtD
Albendazole—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000369	0.00512	CcSEcCtD
Albendazole—ABCB1—epithelium—ovarian cancer	0.000365	0.00643	CbGeAlD
Albendazole—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000362	0.00503	CcSEcCtD
Albendazole—ABCB1—uterine cervix—ovarian cancer	0.000362	0.00637	CbGeAlD
Albendazole—Skin disorder—Vinorelbine—ovarian cancer	0.000359	0.00499	CcSEcCtD
Albendazole—Hypersensitivity—Chlorambucil—ovarian cancer	0.000358	0.00497	CcSEcCtD
Albendazole—Gastrointestinal pain—Topotecan—ovarian cancer	0.000354	0.00491	CcSEcCtD
Albendazole—Pancytopenia—Docetaxel—ovarian cancer	0.000352	0.00489	CcSEcCtD
Albendazole—Neutropenia—Docetaxel—ovarian cancer	0.000347	0.00481	CcSEcCtD
Albendazole—Aplastic anaemia—Doxorubicin—ovarian cancer	0.000346	0.00481	CcSEcCtD
Albendazole—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000346	0.0048	CcSEcCtD
Albendazole—ABCB1—decidua—ovarian cancer	0.000345	0.00607	CbGeAlD
Albendazole—Urticaria—Topotecan—ovarian cancer	0.000343	0.00477	CcSEcCtD
Albendazole—Urethral disorder—Paclitaxel—ovarian cancer	0.000343	0.00476	CcSEcCtD
Albendazole—Body temperature increased—Topotecan—ovarian cancer	0.000342	0.00474	CcSEcCtD
Albendazole—Abdominal pain—Topotecan—ovarian cancer	0.000342	0.00474	CcSEcCtD
Albendazole—Urticaria—Melphalan—ovarian cancer	0.000336	0.00467	CcSEcCtD
Albendazole—Erythema multiforme—Paclitaxel—ovarian cancer	0.000331	0.0046	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.000328	0.00455	CcSEcCtD
Albendazole—ABCB1—endometrium—ovarian cancer	0.000327	0.00577	CbGeAlD
Albendazole—Hypersensitivity—Topotecan—ovarian cancer	0.000319	0.00442	CcSEcCtD
Albendazole—Immune system disorder—Paclitaxel—ovarian cancer	0.000316	0.00439	CcSEcCtD
Albendazole—Renal failure acute—Epirubicin—ovarian cancer	0.000313	0.00435	CcSEcCtD
Albendazole—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000313	0.00434	CcSEcCtD
Albendazole—Hypersensitivity—Melphalan—ovarian cancer	0.000312	0.00433	CcSEcCtD
Albendazole—Alopecia—Paclitaxel—ovarian cancer	0.000309	0.0043	CcSEcCtD
Albendazole—Vomiting—Chlorambucil—ovarian cancer	0.000309	0.00429	CcSEcCtD
Albendazole—Agranulocytosis—Docetaxel—ovarian cancer	0.000308	0.00428	CcSEcCtD
Albendazole—CYP1A1—lymph node—ovarian cancer	0.000305	0.00538	CbGeAlD
Albendazole—ABCB1—gonad—ovarian cancer	0.000304	0.00535	CbGeAlD
Albendazole—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000302	0.0042	CcSEcCtD
Albendazole—ABCB1—uterus—ovarian cancer	0.000302	0.00531	CbGeAlD
Albendazole—Hepatitis—Docetaxel—ovarian cancer	0.000297	0.00412	CcSEcCtD
Albendazole—Urticaria—Vinorelbine—ovarian cancer	0.000294	0.00408	CcSEcCtD
Albendazole—Urinary tract disorder—Docetaxel—ovarian cancer	0.000293	0.00407	CcSEcCtD
Albendazole—Body temperature increased—Vinorelbine—ovarian cancer	0.000292	0.00406	CcSEcCtD
Albendazole—Abdominal pain—Vinorelbine—ovarian cancer	0.000292	0.00406	CcSEcCtD
Albendazole—Urethral disorder—Docetaxel—ovarian cancer	0.000291	0.00404	CcSEcCtD
Albendazole—Renal failure acute—Doxorubicin—ovarian cancer	0.00029	0.00403	CcSEcCtD
Albendazole—Nausea—Chlorambucil—ovarian cancer	0.000288	0.004	CcSEcCtD
Albendazole—Dizziness—Topotecan—ovarian cancer	0.000286	0.00397	CcSEcCtD
Albendazole—Erythema multiforme—Docetaxel—ovarian cancer	0.000281	0.0039	CcSEcCtD
Albendazole—Vomiting—Topotecan—ovarian cancer	0.000275	0.00382	CcSEcCtD
Albendazole—Vertigo—Paclitaxel—ovarian cancer	0.000274	0.0038	CcSEcCtD
Albendazole—Leukopenia—Paclitaxel—ovarian cancer	0.000273	0.00379	CcSEcCtD
Albendazole—Rash—Topotecan—ovarian cancer	0.000273	0.00378	CcSEcCtD
Albendazole—Hypersensitivity—Vinorelbine—ovarian cancer	0.000272	0.00378	CcSEcCtD
Albendazole—Dermatitis—Topotecan—ovarian cancer	0.000272	0.00378	CcSEcCtD
Albendazole—ABCB1—female reproductive system—ovarian cancer	0.000271	0.00478	CbGeAlD
Albendazole—Headache—Topotecan—ovarian cancer	0.000271	0.00376	CcSEcCtD
Albendazole—Vomiting—Melphalan—ovarian cancer	0.000269	0.00374	CcSEcCtD
Albendazole—Immune system disorder—Docetaxel—ovarian cancer	0.000268	0.00372	CcSEcCtD
Albendazole—Liver function test abnormal—Epirubicin—ovarian cancer	0.000267	0.00371	CcSEcCtD
Albendazole—Rash—Melphalan—ovarian cancer	0.000267	0.00371	CcSEcCtD
Albendazole—Dermatitis—Melphalan—ovarian cancer	0.000267	0.0037	CcSEcCtD
Albendazole—Alopecia—Docetaxel—ovarian cancer	0.000262	0.00364	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000258	0.00358	CcSEcCtD
Albendazole—Nausea—Topotecan—ovarian cancer	0.000257	0.00357	CcSEcCtD
Albendazole—ABCB1—bone marrow—ovarian cancer	0.000256	0.00451	CbGeAlD
Albendazole—Nausea—Melphalan—ovarian cancer	0.000251	0.00349	CcSEcCtD
Albendazole—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000247	0.00343	CcSEcCtD
Albendazole—ABCB1—female gonad—ovarian cancer	0.000247	0.00435	CbGeAlD
Albendazole—ABCB1—vagina—ovarian cancer	0.000245	0.00432	CbGeAlD
Albendazole—Dizziness—Vinorelbine—ovarian cancer	0.000245	0.0034	CcSEcCtD
Albendazole—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000244	0.00338	CcSEcCtD
Albendazole—Skin disorder—Paclitaxel—ovarian cancer	0.000242	0.00335	CcSEcCtD
Albendazole—Pancytopenia—Epirubicin—ovarian cancer	0.000237	0.0033	CcSEcCtD
Albendazole—Vomiting—Vinorelbine—ovarian cancer	0.000235	0.00326	CcSEcCtD
Albendazole—Neutropenia—Epirubicin—ovarian cancer	0.000234	0.00325	CcSEcCtD
Albendazole—Rash—Vinorelbine—ovarian cancer	0.000233	0.00324	CcSEcCtD
Albendazole—Dermatitis—Vinorelbine—ovarian cancer	0.000233	0.00323	CcSEcCtD
Albendazole—Headache—Vinorelbine—ovarian cancer	0.000232	0.00322	CcSEcCtD
Albendazole—Leukopenia—Docetaxel—ovarian cancer	0.000231	0.00321	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000221	0.00307	CcSEcCtD
Albendazole—Pancytopenia—Doxorubicin—ovarian cancer	0.00022	0.00305	CcSEcCtD
Albendazole—Nausea—Vinorelbine—ovarian cancer	0.00022	0.00305	CcSEcCtD
Albendazole—ABCB1—testis—ovarian cancer	0.000219	0.00385	CbGeAlD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000218	0.00303	CcSEcCtD
Albendazole—Neutropenia—Doxorubicin—ovarian cancer	0.000216	0.003	CcSEcCtD
Albendazole—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000211	0.00293	CcSEcCtD
Albendazole—Agranulocytosis—Epirubicin—ovarian cancer	0.000208	0.00289	CcSEcCtD
Albendazole—Thrombocytopenia—Docetaxel—ovarian cancer	0.000206	0.00287	CcSEcCtD
Albendazole—Skin disorder—Docetaxel—ovarian cancer	0.000205	0.00284	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000205	0.00284	CcSEcCtD
Albendazole—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000203	0.00282	CcSEcCtD
Albendazole—Hepatitis—Epirubicin—ovarian cancer	0.0002	0.00278	CcSEcCtD
Albendazole—Urinary tract disorder—Epirubicin—ovarian cancer	0.000198	0.00274	CcSEcCtD
Albendazole—Urticaria—Paclitaxel—ovarian cancer	0.000198	0.00274	CcSEcCtD
Albendazole—Body temperature increased—Paclitaxel—ovarian cancer	0.000197	0.00273	CcSEcCtD
Albendazole—Abdominal pain—Paclitaxel—ovarian cancer	0.000197	0.00273	CcSEcCtD
Albendazole—Urethral disorder—Epirubicin—ovarian cancer	0.000196	0.00272	CcSEcCtD
Albendazole—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000195	0.00271	CcSEcCtD
Albendazole—Agranulocytosis—Doxorubicin—ovarian cancer	0.000193	0.00267	CcSEcCtD
Albendazole—Erythema multiforme—Epirubicin—ovarian cancer	0.000189	0.00263	CcSEcCtD
Albendazole—Hepatitis—Doxorubicin—ovarian cancer	0.000185	0.00257	CcSEcCtD
Albendazole—Hypersensitivity—Paclitaxel—ovarian cancer	0.000183	0.00254	CcSEcCtD
Albendazole—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000183	0.00254	CcSEcCtD
Albendazole—Urethral disorder—Doxorubicin—ovarian cancer	0.000182	0.00252	CcSEcCtD
Albendazole—Immune system disorder—Epirubicin—ovarian cancer	0.000181	0.00251	CcSEcCtD
Albendazole—Alopecia—Epirubicin—ovarian cancer	0.000177	0.00246	CcSEcCtD
Albendazole—Erythema multiforme—Doxorubicin—ovarian cancer	0.000175	0.00243	CcSEcCtD
Albendazole—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000172	0.00239	CcSEcCtD
Albendazole—Immune system disorder—Doxorubicin—ovarian cancer	0.000167	0.00232	CcSEcCtD
Albendazole—Abdominal pain—Docetaxel—ovarian cancer	0.000167	0.00231	CcSEcCtD
Albendazole—Body temperature increased—Docetaxel—ovarian cancer	0.000167	0.00231	CcSEcCtD
Albendazole—Dizziness—Paclitaxel—ovarian cancer	0.000164	0.00228	CcSEcCtD
Albendazole—Alopecia—Doxorubicin—ovarian cancer	0.000164	0.00227	CcSEcCtD
Albendazole—ABCB1—lymph node—ovarian cancer	0.000159	0.00279	CbGeAlD
Albendazole—Vomiting—Paclitaxel—ovarian cancer	0.000158	0.0022	CcSEcCtD
Albendazole—Rash—Paclitaxel—ovarian cancer	0.000157	0.00218	CcSEcCtD
Albendazole—Dermatitis—Paclitaxel—ovarian cancer	0.000157	0.00218	CcSEcCtD
Albendazole—Vertigo—Epirubicin—ovarian cancer	0.000157	0.00217	CcSEcCtD
Albendazole—Leukopenia—Epirubicin—ovarian cancer	0.000156	0.00217	CcSEcCtD
Albendazole—Headache—Paclitaxel—ovarian cancer	0.000156	0.00216	CcSEcCtD
Albendazole—Hypersensitivity—Docetaxel—ovarian cancer	0.000155	0.00216	CcSEcCtD
Albendazole—Nausea—Paclitaxel—ovarian cancer	0.000148	0.00205	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000147	0.00205	CcSEcCtD
Albendazole—Vertigo—Doxorubicin—ovarian cancer	0.000145	0.00201	CcSEcCtD
Albendazole—Leukopenia—Doxorubicin—ovarian cancer	0.000144	0.002	CcSEcCtD
Albendazole—Dizziness—Docetaxel—ovarian cancer	0.000139	0.00194	CcSEcCtD
Albendazole—Thrombocytopenia—Epirubicin—ovarian cancer	0.000139	0.00193	CcSEcCtD
Albendazole—Skin disorder—Epirubicin—ovarian cancer	0.000138	0.00192	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000136	0.00189	CcSEcCtD
Albendazole—Vomiting—Docetaxel—ovarian cancer	0.000134	0.00186	CcSEcCtD
Albendazole—Rash—Docetaxel—ovarian cancer	0.000133	0.00185	CcSEcCtD
Albendazole—Dermatitis—Docetaxel—ovarian cancer	0.000133	0.00184	CcSEcCtD
Albendazole—Headache—Docetaxel—ovarian cancer	0.000132	0.00183	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle—RBL2—ovarian cancer	0.00013	0.00218	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—YAP1—ovarian cancer	0.00013	0.00218	CbGpPWpGaD
Albendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.00013	0.00217	CbGpPWpGaD
Albendazole—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000129	0.00179	CcSEcCtD
Albendazole—Skin disorder—Doxorubicin—ovarian cancer	0.000128	0.00177	CcSEcCtD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—ovarian cancer	0.000127	0.00213	CbGpPWpGaD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000127	0.00213	CbGpPWpGaD
Albendazole—Nausea—Docetaxel—ovarian cancer	0.000125	0.00174	CcSEcCtD
Albendazole—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000124	0.00207	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000124	0.00207	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000124	0.00207	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000123	0.00206	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000122	0.00204	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—ovarian cancer	0.000121	0.00203	CbGpPWpGaD
Albendazole—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.00012	0.002	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CHEK2—ovarian cancer	0.000118	0.00197	CbGpPWpGaD
Albendazole—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000116	0.00161	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000116	0.00194	CbGpPWpGaD
Albendazole—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000116	0.00194	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000114	0.00191	CbGpPWpGaD
Albendazole—Urticaria—Epirubicin—ovarian cancer	0.000113	0.00157	CcSEcCtD
Albendazole—Body temperature increased—Epirubicin—ovarian cancer	0.000112	0.00156	CcSEcCtD
Albendazole—Abdominal pain—Epirubicin—ovarian cancer	0.000112	0.00156	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—BRCA1—ovarian cancer	0.00011	0.00184	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CCND2—ovarian cancer	0.00011	0.00184	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000108	0.0018	CbGpPWpGaD
Albendazole—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000108	0.00149	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000106	0.00177	CbGpPWpGaD
Albendazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000105	0.00176	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.000105	0.00176	CbGpPWpGaD
Albendazole—Hypersensitivity—Epirubicin—ovarian cancer	0.000105	0.00145	CcSEcCtD
Albendazole—Urticaria—Doxorubicin—ovarian cancer	0.000105	0.00145	CcSEcCtD
Albendazole—Body temperature increased—Doxorubicin—ovarian cancer	0.000104	0.00144	CcSEcCtD
Albendazole—Abdominal pain—Doxorubicin—ovarian cancer	0.000104	0.00144	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—PPP2R1A—ovarian cancer	0.000104	0.00174	CbGpPWpGaD
Albendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.0001	0.00168	CbGpPWpGaD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.0001	0.00167	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—BRCA2—ovarian cancer	9.96e-05	0.00167	CbGpPWpGaD
Albendazole—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	9.88e-05	0.00165	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—SKP2—ovarian cancer	9.7e-05	0.00162	CbGpPWpGaD
Albendazole—Hypersensitivity—Doxorubicin—ovarian cancer	9.69e-05	0.00135	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—CCNE1—ovarian cancer	9.65e-05	0.00161	CbGpPWpGaD
Albendazole—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	9.56e-05	0.0016	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—TUBB3—ovarian cancer	9.54e-05	0.0016	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—BIRC5—ovarian cancer	9.53e-05	0.00159	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TYMS—ovarian cancer	9.47e-05	0.00158	CbGpPWpGaD
Albendazole—Dizziness—Epirubicin—ovarian cancer	9.4e-05	0.00131	CcSEcCtD
Albendazole—Vomiting—Epirubicin—ovarian cancer	9.04e-05	0.00126	CcSEcCtD
Albendazole—Rash—Epirubicin—ovarian cancer	8.97e-05	0.00124	CcSEcCtD
Albendazole—Dermatitis—Epirubicin—ovarian cancer	8.96e-05	0.00124	CcSEcCtD
Albendazole—Headache—Epirubicin—ovarian cancer	8.91e-05	0.00124	CcSEcCtD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	8.78e-05	0.00147	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MLH1—ovarian cancer	8.77e-05	0.00147	CbGpPWpGaD
Albendazole—Dizziness—Doxorubicin—ovarian cancer	8.7e-05	0.00121	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle—SKP2—ovarian cancer	8.68e-05	0.00145	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—BIRC5—ovarian cancer	8.52e-05	0.00142	CbGpPWpGaD
Albendazole—Nausea—Epirubicin—ovarian cancer	8.45e-05	0.00117	CcSEcCtD
Albendazole—Vomiting—Doxorubicin—ovarian cancer	8.37e-05	0.00116	CcSEcCtD
Albendazole—Rash—Doxorubicin—ovarian cancer	8.3e-05	0.00115	CcSEcCtD
Albendazole—Dermatitis—Doxorubicin—ovarian cancer	8.29e-05	0.00115	CcSEcCtD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	8.29e-05	0.00139	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	8.29e-05	0.00139	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TERT—ovarian cancer	8.25e-05	0.00138	CbGpPWpGaD
Albendazole—Headache—Doxorubicin—ovarian cancer	8.24e-05	0.00114	CcSEcCtD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—TERT—ovarian cancer	8.19e-05	0.00137	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	8.11e-05	0.00136	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	8.11e-05	0.00136	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—ATF3—ovarian cancer	8.06e-05	0.00135	CbGpPWpGaD
Albendazole—Nausea—Doxorubicin—ovarian cancer	7.82e-05	0.00109	CcSEcCtD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	7.77e-05	0.0013	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	7.73e-05	0.00129	CbGpPWpGaD
Albendazole—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	7.62e-05	0.00128	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CCND2—ovarian cancer	7.44e-05	0.00124	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	7.16e-05	0.0012	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CHEK2—ovarian cancer	7.1e-05	0.00119	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	7.02e-05	0.00117	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.01e-05	0.00117	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	6.89e-05	0.00115	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	6.81e-05	0.00114	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.77e-05	0.00113	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—CYP1B1—ovarian cancer	6.76e-05	0.00113	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—CYP1B1—ovarian cancer	6.67e-05	0.00112	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—BRCA1—ovarian cancer	6.65e-05	0.00111	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CCND2—ovarian cancer	6.65e-05	0.00111	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CCNE1—ovarian cancer	6.51e-05	0.00109	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—TYMS—ovarian cancer	6.4e-05	0.00107	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	6.34e-05	0.00106	CbGpPWpGaD
Albendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	6.29e-05	0.00105	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—PPP2R1A—ovarian cancer	6.27e-05	0.00105	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	6.26e-05	0.00105	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	6.2e-05	0.00104	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	6.2e-05	0.00104	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	6.2e-05	0.00104	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—BRCA2—ovarian cancer	6.01e-05	0.00101	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	5.86e-05	0.00098	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CCNE1—ovarian cancer	5.82e-05	0.000974	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—BIRC5—ovarian cancer	5.75e-05	0.000962	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TYMS—ovarian cancer	5.72e-05	0.000957	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	5.59e-05	0.000935	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	5.45e-05	0.000912	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.34e-05	0.000894	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CCND1—ovarian cancer	5.33e-05	0.000892	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	5.28e-05	0.000884	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	5.28e-05	0.000884	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.21e-05	0.000872	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	5.17e-05	0.000865	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—BIRC5—ovarian cancer	5.14e-05	0.00086	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—MMP2—ovarian cancer	5.14e-05	0.000859	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CDKN1B—ovarian cancer	5e-05	0.000836	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TERT—ovarian cancer	4.98e-05	0.000834	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	4.98e-05	0.000833	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	4.98e-05	0.000833	CbGpPWpGaD
Albendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	4.82e-05	0.000806	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CCND1—ovarian cancer	4.77e-05	0.000798	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	4.67e-05	0.000781	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—MAPK3—ovarian cancer	4.4e-05	0.000736	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	4.4e-05	0.000736	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	4.4e-05	0.000735	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	4.34e-05	0.000726	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	4.31e-05	0.000721	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—MYC—ovarian cancer	4.28e-05	0.000716	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CXCL8—ovarian cancer	4.27e-05	0.000714	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	4.25e-05	0.000711	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	4.22e-05	0.000706	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	4.21e-05	0.000704	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CASP3—ovarian cancer	4.21e-05	0.000704	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—IL2—ovarian cancer	4.2e-05	0.000703	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—MAPK1—ovarian cancer	4.19e-05	0.0007	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	4.12e-05	0.00069	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NME2—ovarian cancer	4.12e-05	0.000689	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	4.09e-05	0.000684	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	4.04e-05	0.000676	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	4.04e-05	0.000675	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	4.02e-05	0.000672	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	3.96e-05	0.000662	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	3.96e-05	0.000662	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	3.96e-05	0.000662	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CTNNB1—ovarian cancer	3.94e-05	0.000659	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MAPK3—ovarian cancer	3.93e-05	0.000658	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MYC—ovarian cancer	3.83e-05	0.00064	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MAPK1—ovarian cancer	3.74e-05	0.000626	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	3.74e-05	0.000625	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	3.57e-05	0.000597	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.5e-05	0.000585	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	3.38e-05	0.000565	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	3.33e-05	0.000556	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	3.32e-05	0.000556	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NME2—ovarian cancer	3.29e-05	0.000551	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.28e-05	0.000549	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CCND1—ovarian cancer	3.22e-05	0.000539	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	3.19e-05	0.000534	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	3.18e-05	0.000531	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TP53—ovarian cancer	3.14e-05	0.000526	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	3.12e-05	0.000522	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—MMP2—ovarian cancer	3.1e-05	0.000519	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDKN1B—ovarian cancer	3.02e-05	0.000505	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	2.95e-05	0.000493	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CCND1—ovarian cancer	2.88e-05	0.000482	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.85e-05	0.000477	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—MAPK3—ovarian cancer	2.66e-05	0.000444	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYTB—ovarian cancer	2.66e-05	0.000444	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	2.63e-05	0.00044	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NME2—ovarian cancer	2.63e-05	0.00044	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.6e-05	0.000434	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—MYC—ovarian cancer	2.58e-05	0.000432	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CXCL8—ovarian cancer	2.58e-05	0.000431	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—MAPK1—ovarian cancer	2.53e-05	0.000423	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CTNNB1—ovarian cancer	2.38e-05	0.000398	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MAPK3—ovarian cancer	2.38e-05	0.000397	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—BRIP1—ovarian cancer	2.32e-05	0.000388	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PPP1CC—ovarian cancer	2.32e-05	0.000388	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MYC—ovarian cancer	2.31e-05	0.000386	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.29e-05	0.000383	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MAPK1—ovarian cancer	2.26e-05	0.000378	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.23e-05	0.000373	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.13e-05	0.000356	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYTB—ovarian cancer	2.12e-05	0.000355	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.12e-05	0.000355	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.08e-05	0.000347	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.06e-05	0.000344	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NME2—ovarian cancer	2.03e-05	0.000339	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.02e-05	0.000338	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2e-05	0.000335	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	1.95e-05	0.000326	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TP53—ovarian cancer	1.9e-05	0.000317	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PPP1CC—ovarian cancer	1.85e-05	0.00031	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—BRIP1—ovarian cancer	1.85e-05	0.00031	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.82e-05	0.000304	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.76e-05	0.000295	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYTB—ovarian cancer	1.69e-05	0.000283	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.69e-05	0.000283	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.67e-05	0.000279	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.66e-05	0.000277	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.62e-05	0.000271	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.59e-05	0.000265	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.59e-05	0.000265	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—YAP1—ovarian cancer	1.56e-05	0.00026	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.54e-05	0.000258	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.5e-05	0.000251	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PPP1CC—ovarian cancer	1.48e-05	0.000248	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—BRIP1—ovarian cancer	1.48e-05	0.000248	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.38e-05	0.00023	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.35e-05	0.000227	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.33e-05	0.000223	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYTB—ovarian cancer	1.31e-05	0.000219	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—FASN—ovarian cancer	1.27e-05	0.000212	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SLC5A5—ovarian cancer	1.25e-05	0.000209	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—YAP1—ovarian cancer	1.24e-05	0.000208	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SLC2A1—ovarian cancer	1.21e-05	0.000202	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.18e-05	0.000198	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYP1B1—ovarian cancer	1.16e-05	0.000193	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.14e-05	0.000191	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.14e-05	0.000191	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.12e-05	0.000188	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.08e-05	0.00018	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	1.03e-05	0.000172	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.02e-05	0.000171	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—FASN—ovarian cancer	1.01e-05	0.00017	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SLC5A5—ovarian cancer	9.97e-06	0.000167	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—YAP1—ovarian cancer	9.93e-06	0.000166	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.83e-06	0.000164	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SLC2A1—ovarian cancer	9.63e-06	0.000161	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—ABCB1—ovarian cancer	9.52e-06	0.000159	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—TYMS—ovarian cancer	9.35e-06	0.000156	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYP1B1—ovarian cancer	9.23e-06	0.000154	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.64e-06	0.000144	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PPP2R1A—ovarian cancer	8.19e-06	0.000137	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—FASN—ovarian cancer	8.09e-06	0.000135	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SLC5A5—ovarian cancer	7.96e-06	0.000133	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SLC2A1—ovarian cancer	7.69e-06	0.000129	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—YAP1—ovarian cancer	7.66e-06	0.000128	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CAV1—ovarian cancer	7.53e-06	0.000126	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.53e-06	0.000126	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—TYMS—ovarian cancer	7.47e-06	0.000125	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYP1B1—ovarian cancer	7.37e-06	0.000123	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.2e-06	0.00012	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PIK3CG—ovarian cancer	6.86e-06	0.000115	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	6.54e-06	0.000109	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.51e-06	0.000109	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—FASN—ovarian cancer	6.25e-06	0.000104	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SLC5A5—ovarian cancer	6.14e-06	0.000103	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—ABCB1—ovarian cancer	6.07e-06	0.000102	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PIK3CD—ovarian cancer	6.03e-06	0.000101	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CAV1—ovarian cancer	6.02e-06	0.000101	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—TYMS—ovarian cancer	5.96e-06	9.97e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.93e-06	9.93e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.69e-06	9.52e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.48e-06	9.17e-05	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PIK3CB—ovarian cancer	5.26e-06	8.8e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.05e-06	8.44e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.82e-06	8.06e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CAV1—ovarian cancer	4.8e-06	8.04e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.69e-06	7.84e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—TYMS—ovarian cancer	4.6e-06	7.7e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.59e-06	7.68e-05	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PTEN—ovarian cancer	4.54e-06	7.6e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PIK3CG—ovarian cancer	4.38e-06	7.32e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.2e-06	7.03e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.85e-06	6.43e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CAV1—ovarian cancer	3.71e-06	6.2e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PTEN—ovarian cancer	3.63e-06	6.07e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.38e-06	5.65e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3.35e-06	5.61e-05	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PIK3CA—ovarian cancer	3.21e-06	5.36e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.97e-06	4.97e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PTEN—ovarian cancer	2.9e-06	4.85e-05	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AKT1—ovarian cancer	2.62e-06	4.38e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.59e-06	4.33e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.56e-06	4.28e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PTEN—ovarian cancer	2.24e-06	3.74e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AKT1—ovarian cancer	2.09e-06	3.5e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.04e-06	3.42e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AKT1—ovarian cancer	1.67e-06	2.79e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.58e-06	2.64e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AKT1—ovarian cancer	1.29e-06	2.16e-05	CbGpPWpGaD
